Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020

被引：0
|
作者：
Luka Flegar
Smita George Thoduka
Damiano Librizzi
Markus Luster
Aristeidis Zacharis
Hendrik Heers
Nicole Eisenmenger
Hojjat Ahmadzadehfar
Matthias Eiber
Wolfgang Weber
Christer Groeben
Johannes Huber
机构：
[1] Philipps-University Marburg,Department of Urology
[2] Philipps-University Marburg,Department of Nuclear Medicine
[3] Reimbursement Institute,Department of Nuclear Medicine
[4] Klinikum Westfalen GmbH,Department of Nuclear Medicine
[5] Technische Universität Munich,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2023年 / 50卷
关键词：
Prostate cancer; mCRPC; Lutetium-; PSMA (; Lu-PSMA); Radioligand therapy; Health services research; Trends;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2188 / 2195
页数：7
相关论文
共 50 条
  • [1] Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020
    Flegar, Luka
    Thoduka, Smita George
    Librizzi, Damiano
    Luster, Markus
    Zacharis, Aristeidis
    Heers, Hendrik
    Eisenmenger, Nicole
    Ahmadzadehfar, Hojjat
    Eiber, Matthias
    Weber, Wolfgang
    Groeben, Christer
    Huber, Johannes
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (07) : 2188 - 2195
  • [2] Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer in Germany: Population-based data with multicenter validation from 2016 to 2020.
    Flegar, Luka
    Thoduka, Smita George
    Librizzi, Damiano
    Luster, Markus
    Zacharis, Aristeidis
    Heers, Hendrik
    Eisenmenger, Nicole
    Ahmadzadehfar, Hojjat
    Eiber, Matthias
    Weber, Wolfgang A.
    Groeben, Christer
    Huber, Johannes
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] Efficacy and safety of Lutetium-177 PSMA radioligand therapy versus Docetaxel in metastatic castration resistant prostate cancer - preliminary results of a randomized controlled trial
    Satapathy, Swayamjeet
    Mittal, Bhagwant
    Sood, Ashwani
    Bhattacharya, Anish
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [4] Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
    Kinikoglu, Oguzcan
    Oven, Bala Basak
    Celik, Serkan
    Selcuk, Nalan Alan
    Beydagi, Gamze
    Akcay, Kaan
    Kabasakal, Levent
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
  • [5] Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review
    Patell, Kanchi
    Kurian, Matthew
    Garcia, Jorge A.
    Mendiratta, Prateek
    Barata, Pedro C.
    Jia, Angela Y.
    Spratt, Daniel E.
    Brown, Jason R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (07) : 731 - 744
  • [6] The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study
    Almuradova, Elvina
    Seyyar, Mustafa
    Arak, Haci
    Tamer, Fatih
    Kefeli, Umut
    Koca, Sinan
    Sen, Erdem
    Telli, Tugba Akin
    Karatas, Fatih
    Gokmen, Ivo
    Turhal, Nazim Serdar
    Sakalar, Teoman
    Ayhan, Murat
    Ekinci, Ferhat
    Hafizoglu, Emre
    Kahraman, Seda
    Kesen, Oguzhan
    Unal, Caglar
    Alan, Ozkan
    Celik, Serdar
    Yekeduz, Emre
    Omur, Ozgur
    Gokmen, Erhan
    INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (04) : 692 - 700
  • [7] 177Lutetium PSMA radioligand therapy in prostate cancer
    Vis A.N.
    Jansen B.H.E.
    Bodar Y.J.L.
    Nieuwenhuijzen J.A.
    Hendrikse H.N.
    Oprea-Lager D.E.
    Tijdschrift voor Urologie, 2020, 10 (4) : 60 - 65
  • [8] Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    Sartor, Oliver
    de Bono, Johann
    Chi, Kim N.
    Fizazi, Karim
    Herrmann, Ken
    Rahbar, Kambiz
    Tagawa, Scott T.
    Nordquist, Luke T.
    Vaishampayan, Nitin
    El-Haddad, Ghassan
    Park, Chandler H.
    Beer, Tomasz M.
    Armour, Alison
    Perez-Contreras, Wendy J.
    DeSilvio, Michelle
    Kpamegan, Euloge
    Gericke, Germo
    Messmann, Richard A.
    Morris, Michael J.
    Krause, Bernd J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12): : 1091 - 1103
  • [9] Cost Utility Analysis of 177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Germany
    Stargardt, T.
    Brinkmann, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S827 - S827
  • [10] Genetic analysis of metastatic castration resistant prostate cancer patients treated with Lu-177 PSMA radioligand therapy
    Yilmaz, Burcak
    Chalker, Cameron
    Yu, Yun
    Kaempf, Andy
    Mittra, Erik
    Mallak, Nadine
    Sokolova, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345